January 30, 2024 News by Margarida Maia, PhD Cell-based therapy can be produced in under 3 days from blood sample Kyverna Therapeutics has developed a method that enables KYV-101, an experimental CAR T-cell therapy for multiple sclerosis (MS) and other conditions, to be produced in a much shorter timeframe than conventional manufacturing processes, a study shows. The approach took less than three…
November 10, 2023 News by Marisa Wexler, MS ATA188 fails to outperform placebo in EMBOLD clinical trial ATA188, an experimental cell therapy targeting the Epstein-Barr virus, failed to outperform a placebo at easing disability levels in people with nonactive progressive forms of multiple sclerosis (MS), according to data from the Phase 2 portion of the EMBOLD clinical trial. The medication also showed no signs of…
December 8, 2022 News by Marisa Wexler, MS Novel CAR T-cell Therapy Shows Promise in MS Mouse Study Researchers have developed a technique that uses CAR T-cells, a form of cell therapy, to specifically eliminate the self-reactive immune cells that drive multiple sclerosis (MS), without destroying healthy immune cells needed to protect against infection. “Our CAR-T cells were very effective at treating mice that have an MS-like…
October 12, 2022 News by Marisa Wexler, MS Partnership Aims at Cell Therapy Targeting Epstein-Barr Virus in MS NexImmune is working with the National Institute of Neurological Disorders and Stroke (NINDS) to develop cell therapies for people with immunological disorders associated with certain viral infections, namely the Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-1). A history of infection with EBV ā mostly…
June 6, 2022 News by Lindsey Shapiro, PhD Fibroblast Cell Therapy Shows Early Promise in MS Patients A single infusion of FibroBiologics‘ investigational cell therapy, CYMS101, was able to inhibit disease activity in a mouse model of multiple sclerosis (MS), and appeared safe in early MS clinical trials, the company announced in a press release. Data from the mouse and human studies were…
June 29, 2021 News by Margarida Maia, PhD Abata Opens With Plans to Develop T-cell Therapies for Progressive MS Abata Therapeutics has opened with $95 million in financing, and plans to use regulatory T-cells to treat autoimmune and inflammatory diseases, starting with progressive forms ofĀ multiple sclerosis (MS). Money raised will be used to support work for three clinical trials it plans to initiate in 2025, including…
March 26, 2021 News by Vanda Pinto, PhD NurOwn Cell Therapy Found Safe, Effective for Progressive MS in Phase 2 Trial NurOwn cell therapy led to significant improvements in the physical abilities, vision, and cognition of people withĀ progressive multiple sclerosis (MS) in a Phase 2 clinical trial, top-line data show. In addition to these positive efficacy results, BrainStorm Cell Therapeutics, NurOwn’s developer, announced that its cell-based therapy showed…
December 2, 2019 News by Alice MelĆ£o, MSc Mount Sinai Taking Part in Phase 2 Trial of NurOwn Cell Therapy in Progressive MS Mount Sinai Medical Center has joined withĀ BrainStorm Cell Therapeutics to explore the safety and efficacy of NurOwn as a potential treatment for progressive multiple sclerosis (MS) in an ongoing Phase 2 trial. The New York center is the fourth clinical site participating in the trial, in addition…
November 29, 2018 News by Ana Pena PhD Stem Cells With Unusual Metabolism May Be Therapeutic Approach to Fight Inflammatory Diseases Like MS, Study Suggests Human mesenchymal stem cells (hMSCs), the type of stem cells present in many tissues of adults, may be manipulated to fight inflammation and used as a cell therapy to treat inflammatory diseases like multiple sclerosis (MS), a study reports. In the future, researchers plan to use animal models to…
November 21, 2018 News by Patricia Inacio, PhD Phase 1 Trial of ATA190 Cell Therapy Shows Promise in Treating Progressive MS Atara Biotherapeuticsā investigational ATA190, a cell therapy that wipes out immune B-cells infected with the Epstein-Barr virus (EBV), led to neurological improvements and reduced symptoms in patients with primary and secondary progressive multiple sclerosis (MS), a Phase 1 trial shows. The trial results were published in the Journal…
July 31, 2017 Columns by Ed Tobias MS News That Caught My Eye This Week: Myelin Repair, Ocrevus and Insurance, Cell Therapies In case you missedĀ them, here are some news stories that appeared in MS News Today that caught my eye over the past week: Q Therapeutics Approved to Start Trial of Cell Therapy Aiming to Restore Myelins Those of us with MS know that if something can…
July 26, 2017 News by Patricia Silva, PhD Q Therapeutics Approved to Start Trial of Cell Therapy Aiming to Restore Myelin A cell therapy intended to boostĀ myelin regeneration ā Q-Cells byĀ Q TherapeuticsĀ āĀ has received aĀ green light from the U.S. Food and Drug Administration to proceed with a clinical trial in patients with transverse myelitis (TM), a disease that likeĀ multiple sclerosis is characterized by myelin damage. FDA approval of the companyās Investigational New…